{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.1, "width": 2200, "height": 1736, "unit": "pixel", "lines": [{"boundingBox": [145, 126, 1166, 138, 1165, 247, 143, 234], "text": "CSF's and Marketing", "words": [{"boundingBox": [151, 135, 435, 134, 436, 232, 153, 229], "text": "CSF's"}, {"boundingBox": [453, 134, 638, 135, 639, 236, 454, 233], "text": "and"}, {"boundingBox": [656, 135, 1162, 139, 1162, 249, 657, 236], "text": "Marketing"}]}, {"boundingBox": [1809, 134, 1987, 133, 1988, 162, 1810, 163], "text": "Thegys Q0 Power", "words": [{"boundingBox": [1812, 135, 1875, 134, 1874, 163, 1811, 163], "text": "Thegys", "confidence": "Low"}, {"boundingBox": [1881, 134, 1912, 134, 1911, 163, 1880, 163], "text": "Q0", "confidence": "Low"}, {"boundingBox": [1917, 134, 1987, 134, 1987, 163, 1917, 163], "text": "Power", "confidence": "Low"}]}, {"boundingBox": [1799, 165, 2076, 164, 2076, 227, 1800, 229], "text": "actos", "words": [{"boundingBox": [1809, 166, 2067, 164, 2064, 229, 1810, 229], "text": "actos"}]}, {"boundingBox": [140, 263, 696, 263, 695, 375, 139, 374], "text": "Objectives*", "words": [{"boundingBox": [140, 263, 692, 265, 688, 373, 147, 375], "text": "Objectives*"}]}, {"boundingBox": [1801, 234, 2071, 228, 2072, 272, 1802, 278], "text": "pioglitazone HCI", "words": [{"boundingBox": [1805, 235, 2004, 231, 2006, 273, 1806, 279], "text": "pioglitazone"}, {"boundingBox": [2013, 230, 2070, 229, 2072, 272, 2014, 273], "text": "HCI"}]}, {"boundingBox": [1804, 287, 2069, 290, 2068, 321, 1803, 319], "text": "For performance that", "words": [{"boundingBox": [1809, 288, 1848, 290, 1847, 319, 1808, 318], "text": "For"}, {"boundingBox": [1854, 290, 2011, 291, 2010, 321, 1853, 319], "text": "performance"}, {"boundingBox": [2017, 291, 2070, 290, 2069, 320, 2016, 321], "text": "that"}]}, {"boundingBox": [1806, 318, 2017, 320, 2016, 350, 1805, 348], "text": "benefits the body.", "words": [{"boundingBox": [1807, 319, 1901, 320, 1901, 349, 1806, 349], "text": "benefits"}, {"boundingBox": [1907, 320, 1946, 320, 1945, 350, 1907, 349], "text": "the"}, {"boundingBox": [1951, 320, 2015, 321, 2015, 351, 1951, 350], "text": "body.", "confidence": "Low"}]}, {"boundingBox": [150, 384, 2047, 385, 2046, 436, 149, 435], "text": "CSF #1- Condition the market on IR and its link to CV risk including lipid abnormalities", "words": [{"boundingBox": [156, 386, 245, 386, 245, 436, 157, 436], "text": "CSF"}, {"boundingBox": [255, 386, 327, 386, 327, 436, 255, 436], "text": "#1-"}, {"boundingBox": [337, 386, 550, 387, 550, 436, 337, 436], "text": "Condition"}, {"boundingBox": [559, 387, 628, 387, 629, 437, 560, 436], "text": "the"}, {"boundingBox": [638, 387, 799, 387, 799, 437, 639, 437], "text": "market"}, {"boundingBox": [809, 387, 864, 387, 865, 437, 809, 437], "text": "on"}, {"boundingBox": [874, 387, 927, 387, 927, 437, 874, 437], "text": "IR"}, {"boundingBox": [940, 387, 1022, 387, 1022, 437, 940, 437], "text": "and"}, {"boundingBox": [1031, 387, 1084, 387, 1084, 437, 1032, 437], "text": "its"}, {"boundingBox": [1094, 387, 1185, 387, 1186, 437, 1094, 437], "text": "link"}, {"boundingBox": [1195, 387, 1241, 387, 1241, 437, 1195, 437], "text": "to"}, {"boundingBox": [1251, 387, 1320, 387, 1320, 437, 1251, 437], "text": "CV"}, {"boundingBox": [1333, 387, 1418, 387, 1418, 437, 1333, 437], "text": "risk"}, {"boundingBox": [1428, 387, 1628, 386, 1628, 437, 1428, 437], "text": "including"}, {"boundingBox": [1638, 386, 1739, 386, 1739, 437, 1638, 437], "text": "lipid"}, {"boundingBox": [1749, 386, 2047, 385, 2047, 437, 1749, 437], "text": "abnormalities"}]}, {"boundingBox": [151, 446, 600, 445, 601, 496, 152, 497], "text": "Marketing Objectives:", "words": [{"boundingBox": [152, 448, 366, 446, 365, 496, 152, 498], "text": "Marketing"}, {"boundingBox": [375, 446, 602, 448, 602, 496, 375, 496], "text": "Objectives:"}]}, {"boundingBox": [150, 523, 1604, 526, 1603, 575, 149, 572], "text": "1. 50% of MD's will state that IR is their primary treatment focus by end of 2003.", "words": [{"boundingBox": [158, 525, 189, 525, 190, 569, 159, 568], "text": "1."}, {"boundingBox": [198, 525, 282, 526, 283, 570, 198, 569], "text": "50%"}, {"boundingBox": [291, 526, 327, 526, 328, 570, 291, 570], "text": "of"}, {"boundingBox": [336, 527, 440, 527, 440, 572, 336, 570], "text": "MD's"}, {"boundingBox": [449, 527, 519, 528, 519, 572, 449, 572], "text": "will"}, {"boundingBox": [528, 528, 610, 528, 609, 573, 528, 572], "text": "state"}, {"boundingBox": [618, 528, 691, 528, 691, 573, 618, 573], "text": "that"}, {"boundingBox": [700, 528, 742, 529, 742, 574, 700, 573], "text": "IR"}, {"boundingBox": [754, 529, 785, 529, 784, 574, 753, 574], "text": "is"}, {"boundingBox": [793, 529, 878, 529, 877, 574, 793, 574], "text": "their"}, {"boundingBox": [886, 529, 1030, 529, 1029, 574, 886, 574], "text": "primary"}, {"boundingBox": [1039, 529, 1214, 528, 1213, 574, 1038, 574], "text": "treatment"}, {"boundingBox": [1222, 528, 1318, 528, 1317, 574, 1221, 574], "text": "focus"}, {"boundingBox": [1327, 528, 1377, 528, 1376, 573, 1325, 574], "text": "by"}, {"boundingBox": [1386, 528, 1451, 527, 1449, 573, 1384, 573], "text": "end"}, {"boundingBox": [1459, 527, 1502, 527, 1500, 572, 1458, 573], "text": "of"}, {"boundingBox": [1510, 527, 1603, 527, 1601, 572, 1508, 572], "text": "2003."}]}, {"boundingBox": [153, 618, 1357, 620, 1356, 670, 152, 668], "text": "2. 50% of MD's will believe TZDs reduce CV risk by end of 2003.", "words": [{"boundingBox": [156, 621, 202, 622, 203, 666, 157, 665], "text": "2."}, {"boundingBox": [210, 622, 292, 623, 292, 666, 211, 666], "text": "50%"}, {"boundingBox": [300, 623, 341, 623, 341, 666, 301, 666], "text": "of"}, {"boundingBox": [349, 623, 451, 624, 451, 667, 350, 666], "text": "MD's"}, {"boundingBox": [459, 624, 529, 624, 529, 667, 460, 667], "text": "will"}, {"boundingBox": [538, 624, 674, 624, 673, 668, 537, 667], "text": "believe"}, {"boundingBox": [682, 624, 784, 624, 783, 668, 682, 668], "text": "TZDs"}, {"boundingBox": [792, 624, 917, 624, 915, 669, 791, 668], "text": "reduce"}, {"boundingBox": [925, 624, 986, 623, 985, 669, 924, 669], "text": "CV"}, {"boundingBox": [995, 623, 1064, 623, 1062, 669, 993, 669], "text": "risk"}, {"boundingBox": [1073, 623, 1122, 623, 1120, 670, 1071, 669], "text": "by"}, {"boundingBox": [1131, 622, 1197, 622, 1195, 670, 1129, 670], "text": "end"}, {"boundingBox": [1206, 622, 1247, 621, 1244, 670, 1204, 670], "text": "of"}, {"boundingBox": [1255, 621, 1357, 620, 1354, 671, 1253, 670], "text": "2003."}]}, {"boundingBox": [155, 760, 1166, 763, 1165, 813, 154, 810], "text": "CSF #2- Differentiate ACTOS Vs. other OAD's", "words": [{"boundingBox": [158, 761, 248, 761, 247, 806, 157, 803], "text": "CSF"}, {"boundingBox": [262, 762, 332, 762, 331, 808, 261, 806], "text": "#2-"}, {"boundingBox": [340, 762, 620, 764, 619, 812, 339, 808], "text": "Differentiate"}, {"boundingBox": [628, 764, 799, 764, 798, 812, 627, 812], "text": "ACTOS"}, {"boundingBox": [816, 764, 883, 764, 882, 812, 814, 812], "text": "Vs."}, {"boundingBox": [892, 764, 1012, 764, 1010, 810, 890, 812], "text": "other"}, {"boundingBox": [1020, 764, 1166, 763, 1164, 807, 1019, 810], "text": "OAD's"}]}, {"boundingBox": [155, 834, 603, 833, 604, 885, 156, 885], "text": "Marketing Objectives:", "words": [{"boundingBox": [156, 836, 365, 835, 366, 885, 157, 884], "text": "Marketing"}, {"boundingBox": [375, 835, 603, 834, 603, 886, 375, 885], "text": "Objectives:"}]}, {"boundingBox": [153, 942, 2008, 942, 2008, 993, 154, 993], "text": "1. 35% of targeted MDs will believe ACTOS is the best oral for patients with type 2 diabetes by end of", "words": [{"boundingBox": [157, 946, 201, 946, 201, 990, 158, 990], "text": "1."}, {"boundingBox": [210, 946, 294, 946, 294, 991, 210, 990], "text": "35%"}, {"boundingBox": [302, 946, 340, 946, 341, 991, 303, 991], "text": "of"}, {"boundingBox": [349, 946, 494, 946, 494, 992, 349, 991], "text": "targeted"}, {"boundingBox": [502, 946, 598, 947, 599, 992, 503, 992], "text": "MDs"}, {"boundingBox": [607, 947, 673, 947, 674, 992, 607, 992], "text": "will"}, {"boundingBox": [682, 947, 818, 947, 819, 993, 683, 992], "text": "believe"}, {"boundingBox": [827, 947, 972, 947, 972, 993, 828, 993], "text": "ACTOS"}, {"boundingBox": [980, 947, 1012, 946, 1013, 993, 981, 993], "text": "is"}, {"boundingBox": [1021, 946, 1076, 946, 1077, 994, 1022, 993], "text": "the"}, {"boundingBox": [1085, 946, 1163, 946, 1164, 994, 1086, 994], "text": "best"}, {"boundingBox": [1172, 946, 1244, 946, 1245, 994, 1172, 994], "text": "oral"}, {"boundingBox": [1253, 946, 1305, 946, 1306, 994, 1254, 994], "text": "for"}, {"boundingBox": [1314, 946, 1456, 945, 1457, 994, 1315, 994], "text": "patients"}, {"boundingBox": [1464, 945, 1546, 945, 1546, 994, 1465, 994], "text": "with"}, {"boundingBox": [1554, 945, 1635, 944, 1636, 994, 1555, 994], "text": "type"}, {"boundingBox": [1644, 944, 1673, 944, 1674, 994, 1645, 994], "text": "2"}, {"boundingBox": [1682, 944, 1824, 943, 1825, 994, 1683, 994], "text": "diabetes"}, {"boundingBox": [1832, 943, 1879, 943, 1880, 994, 1833, 994], "text": "by"}, {"boundingBox": [1888, 943, 1954, 942, 1955, 994, 1888, 994], "text": "end"}, {"boundingBox": [1963, 942, 2006, 942, 2007, 993, 1964, 994], "text": "of"}]}, {"boundingBox": [223, 1000, 326, 999, 327, 1038, 223, 1035], "text": "2003.", "words": [{"boundingBox": [230, 998, 327, 998, 326, 1037, 230, 1037], "text": "2003."}]}, {"boundingBox": [152, 1108, 1176, 1113, 1175, 1166, 151, 1162], "text": "CSF #3- Maintain a Competitive Share of Voice", "words": [{"boundingBox": [159, 1112, 248, 1113, 247, 1157, 158, 1155], "text": "CSF"}, {"boundingBox": [262, 1113, 331, 1113, 330, 1160, 261, 1158], "text": "#3-"}, {"boundingBox": [339, 1113, 539, 1113, 539, 1164, 338, 1160], "text": "Maintain"}, {"boundingBox": [550, 1113, 578, 1113, 577, 1164, 550, 1164], "text": "a"}, {"boundingBox": [589, 1113, 853, 1113, 853, 1166, 589, 1165], "text": "Competitive"}, {"boundingBox": [861, 1113, 989, 1113, 989, 1165, 861, 1166], "text": "Share"}, {"boundingBox": [997, 1113, 1050, 1113, 1050, 1164, 997, 1165], "text": "of"}, {"boundingBox": [1058, 1113, 1175, 1113, 1175, 1162, 1058, 1164], "text": "Voice"}]}, {"boundingBox": [152, 1183, 607, 1186, 606, 1235, 152, 1233], "text": "Marketing Objectives:", "words": [{"boundingBox": [153, 1187, 368, 1186, 367, 1233, 152, 1234], "text": "Marketing"}, {"boundingBox": [377, 1186, 608, 1190, 606, 1236, 376, 1233], "text": "Objectives:"}]}, {"boundingBox": [153, 1240, 1792, 1243, 1791, 1293, 152, 1291], "text": "1. Achieve and maintain parity in sales force SOV with GSK in targeted physicians.", "words": [{"boundingBox": [156, 1244, 207, 1244, 208, 1288, 158, 1287], "text": "1."}, {"boundingBox": [216, 1244, 377, 1244, 378, 1289, 217, 1288], "text": "Achieve"}, {"boundingBox": [386, 1244, 462, 1244, 463, 1290, 387, 1289], "text": "and"}, {"boundingBox": [471, 1244, 641, 1244, 641, 1291, 471, 1290], "text": "maintain"}, {"boundingBox": [649, 1244, 762, 1244, 763, 1292, 650, 1291], "text": "parity"}, {"boundingBox": [771, 1244, 811, 1244, 811, 1292, 771, 1292], "text": "in"}, {"boundingBox": [822, 1244, 927, 1244, 927, 1293, 822, 1292], "text": "sales"}, {"boundingBox": [935, 1244, 1040, 1244, 1040, 1293, 935, 1293], "text": "force"}, {"boundingBox": [1051, 1244, 1142, 1244, 1142, 1293, 1051, 1293], "text": "SOV"}, {"boundingBox": [1153, 1244, 1235, 1244, 1235, 1294, 1153, 1293], "text": "with"}, {"boundingBox": [1247, 1244, 1337, 1244, 1337, 1294, 1246, 1294], "text": "GSK"}, {"boundingBox": [1349, 1244, 1388, 1244, 1388, 1294, 1348, 1294], "text": "in"}, {"boundingBox": [1397, 1244, 1564, 1244, 1563, 1294, 1396, 1294], "text": "targeted"}, {"boundingBox": [1573, 1244, 1791, 1243, 1789, 1294, 1571, 1294], "text": "physicians."}]}, {"boundingBox": [151, 1347, 2076, 1351, 2075, 1400, 150, 1397], "text": "2. OAD decile 7-10 physicians + opinion leaders will perceive they experience more contacts from", "words": [{"boundingBox": [157, 1349, 196, 1350, 196, 1393, 157, 1392], "text": "2."}, {"boundingBox": [204, 1350, 296, 1350, 297, 1394, 205, 1393], "text": "OAD"}, {"boundingBox": [319, 1350, 433, 1350, 434, 1396, 319, 1394], "text": "decile"}, {"boundingBox": [442, 1350, 531, 1350, 532, 1397, 442, 1396], "text": "7-10"}, {"boundingBox": [540, 1350, 755, 1351, 756, 1398, 540, 1397], "text": "physicians"}, {"boundingBox": [763, 1351, 791, 1351, 792, 1399, 764, 1398], "text": "+"}, {"boundingBox": [800, 1351, 942, 1351, 943, 1399, 800, 1399], "text": "opinion"}, {"boundingBox": [951, 1351, 1105, 1351, 1105, 1400, 951, 1399], "text": "leaders"}, {"boundingBox": [1113, 1351, 1174, 1351, 1175, 1400, 1113, 1400], "text": "will"}, {"boundingBox": [1183, 1351, 1356, 1352, 1357, 1400, 1183, 1400], "text": "perceive"}, {"boundingBox": [1365, 1352, 1454, 1352, 1455, 1400, 1365, 1400], "text": "they"}, {"boundingBox": [1462, 1352, 1683, 1352, 1684, 1399, 1463, 1400], "text": "experience"}, {"boundingBox": [1692, 1352, 1798, 1352, 1799, 1399, 1692, 1399], "text": "more"}, {"boundingBox": [1806, 1352, 1977, 1352, 1978, 1397, 1807, 1398], "text": "contacts"}, {"boundingBox": [1985, 1352, 2061, 1351, 2061, 1396, 1986, 1397], "text": "from"}]}, {"boundingBox": [229, 1402, 1084, 1404, 1083, 1452, 228, 1450], "text": "ACTOS than any other oral diabetes agent.", "words": [{"boundingBox": [230, 1403, 385, 1403, 384, 1451, 229, 1450], "text": "ACTOS"}, {"boundingBox": [394, 1403, 485, 1404, 485, 1451, 393, 1451], "text": "than"}, {"boundingBox": [494, 1404, 567, 1404, 567, 1451, 494, 1451], "text": "any"}, {"boundingBox": [576, 1404, 683, 1404, 683, 1452, 576, 1451], "text": "other"}, {"boundingBox": [692, 1404, 777, 1405, 777, 1452, 692, 1452], "text": "oral"}, {"boundingBox": [786, 1405, 950, 1405, 951, 1452, 786, 1452], "text": "diabetes"}, {"boundingBox": [959, 1405, 1084, 1406, 1084, 1452, 960, 1452], "text": "agent."}]}, {"boundingBox": [501, 1502, 1450, 1508, 1450, 1555, 500, 1549], "text": "*NOTE: The percentages used are subject to change", "words": [{"boundingBox": [504, 1507, 671, 1508, 671, 1549, 503, 1546], "text": "*NOTE:"}, {"boundingBox": [681, 1508, 749, 1508, 749, 1550, 681, 1549], "text": "The"}, {"boundingBox": [757, 1508, 971, 1509, 971, 1553, 757, 1550], "text": "percentages"}, {"boundingBox": [979, 1509, 1065, 1509, 1065, 1553, 979, 1553], "text": "used"}, {"boundingBox": [1072, 1509, 1130, 1509, 1131, 1554, 1073, 1553], "text": "are"}, {"boundingBox": [1138, 1509, 1265, 1509, 1266, 1555, 1138, 1554], "text": "subject"}, {"boundingBox": [1273, 1509, 1312, 1509, 1313, 1555, 1274, 1555], "text": "to"}, {"boundingBox": [1320, 1509, 1448, 1508, 1449, 1555, 1321, 1555], "text": "change"}]}, {"boundingBox": [632, 1693, 1567, 1690, 1568, 1730, 633, 1732], "text": "Source: https://www.indupt460g oooogts.ucsf.edu/docs/xqjf0226", "words": [{"boundingBox": [635, 1696, 750, 1697, 750, 1730, 635, 1729], "text": "Source:"}, {"boundingBox": [757, 1697, 1099, 1697, 1099, 1732, 757, 1730], "text": "https://www.indupt460g"}, {"boundingBox": [1108, 1697, 1567, 1691, 1568, 1730, 1108, 1732], "text": "oooogts.ucsf.edu/docs/xqjf0226"}]}]}]}